Bio-Techne and Refeyn launch integrated workflow for bispecific antibody characterization
The workflow combines icIEF fractionation with mass photometry to directly correlate charge and size variants in a four-hour process.
See the latest news and media coverage for Bio-Techne. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer and manufacturer of life-science reagents and instruments
bio-techne.comLast updated
In short: Bio-Techne reported mixed fiscal 2026 financial results while advancing spatial biology and multiomics through new products and partnerships.
The workflow combines icIEF fractionation with mass photometry to directly correlate charge and size variants in a four-hour process.
The new self-labelling technology overcomes limitations in tracking smaller and disease-causing proteins for therapeutic research.
Revenue declines 2% to $311.4M. GAAP EPS rises to $0.32. Adjusted EPS falls to $0.53. Growth in large pharma and spatial biology.
It organizes technologies into R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™ to aid customer navigation from discovery to diagnostics.
Bio-Techne (TECH) has drawn fresh investor interest after teaming up with Refeyn on a four hour integrated workflow that links charge heterogeneity, molecular weight, and...
Activist investor Ananym Capital Management has built a stake in Bio-Techne Corp. and is pushing the board to conduct a strategic review that would include...
Techne (TECH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Shares of Bio-Techne Corp. TECH slipped 3.22% to $43.30 Friday, on what proved to be an all-around grim trading session for the stock market, with...
Track Bio-Techne and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Bio-Techne and other trending companies.